On-site corporate medical services•Pre-employment medical assessments•Annual employee health check-ups•Workplace vaccination programs•Occupational health evaluations•Chronic disease management•Home nursing care•Post-surgery home care•Doctor home visits•Physiotherapy at home•Elderly home care•Lab tests at home•ECG, echo & X-ray at home•Patient Support Programs (PSP)•Medication delivery & adherence follow-up•School medical services & student check-ups•Digital health & tailored health technology•White-label digital health platforms•
Patient Support

Patient Support Program vs Patient Assistance Program in Egypt: What Is the Difference?

9 min readHospitalia Team
Three people wearing lavender scrubs and white coats looking at a tablet in a corridor; the man in the centre wears glasses and the woman on the right wears a lavender headscarf

Quick answer

A plain guide for patients, families and pharma teams in Egypt: what a patient support program is, what a patient assistance program is, why the two terms blur, what the evidence says, and the questions to ask before you enrol.

Short answer: a patient support program (PSP) is a broad service around a treatment, such as education, nurse follow-up, reminders and coordination. A patient assistance program (PAP) is narrower: it helps with the cost of a medicine. The terms overlap, and a PSP often includes financial help, so judge any program by what it promises in writing, not by its name.

  • A 2022 systematic review of patient support programs in Europe (Sacristan et al., The Patient 15(6):641-654) groups PSPs into three kinds of service: helping patients take medicines as prescribed, helping them understand and manage their condition, and providing a service or financial assistance, which it notes is often called a patient assistance program. The authors say the field needs a standard definition.
  • That same review found 49 studies under a broad definition and kept 20 that met the narrower European Medicines Agency definition. All were observational, only 45% had a comparison group, and the authors say no conclusion can be drawn from the comparisons with standard care. The review discloses Eli Lilly funding.
  • GoodRx, a US consumer health site (page updated 28 April 2022), describes patient assistance programs as run by pharmaceutical companies, nonprofits or government agencies to help people without insurance or with inadequate cover afford medicines, sometimes covering the full cost and sometimes giving a discount, usually with income and residency rules and no standard enrolment process.
  • A Newfoundland and Labrador drug plan page listing manufacturer programs for biosimilar medicines shows how the two blend: entries mention reimbursement navigation, financial assistance, bridging support, injection training, nurse or case manager support and delivery. It notes that services may not be available for all products and that one product has no formal program.
  • Egypt example: Roche's Perjeta program report (Access Accelerated, April 2020) describes a pricing scheme of a free vial on each two vials purchased, open to patients who buy the medicine themselves because it is not reimbursed in the public system. The same program also ran a call centre that registered patients and sent reminders. Its figures are sponsor-reported.
  • We found no Egyptian regulation or official definition that separates the two terms, and we do not state one. The label patient assistance program appears mainly in North American sources.

Patient support program vs patient assistance program: the short version

The table below shows the typical pattern. It is a guide, not a rule, because the terms are not standardised and each sponsor designs its own program.

QuestionPatient support program (PSP)Patient assistance program (PAP)
Main aimHelp a person start and stay on a prescribed treatmentHelp a person afford or obtain a medicine
Typical servicesOnboarding, education, reminders, nurse calls or visits, appointment coordination, sometimes testing supportFree or discounted medicine, a bridging supply, or other help with cost
Who usually runs itOften a manufacturer, with nurses, a pharmacy or a call centre working for the sponsorManufacturers, nonprofits or government agencies (per GoodRx, US)
Who qualifiesDefined by each program: medicine, diagnosis, prescription, areaOften coverage or income criteria (per GoodRx, US)
What to ask firstWhat exactly will I receive, and how is my data used?What will I pay, and what must I prove?
Typical differences between a PSP and a PAP (patterns from the sources cited; programs vary)

Why the two terms blur

The Sacristan review uses two definitions. The broad one describes enhanced self-management support, for example individual medication counselling. The narrow one, from the European Medicines Agency, describes an organised system through which a marketing authorisation holder receives and collects information. Under the broad definition, financial assistance sits inside the PSP family; under the narrow one it may not. A July 2026 article in Pharmaceutical Commerce does the same: it lists clinical support, case management, financial assistance and technology as four core service categories of a patient hub. So a leaflet that says support may describe education only, a price scheme only or both. The word on the front does not tell you which.

What a patient assistance program usually looks like

In the US sources we reviewed, a PAP is built around affordability. GoodRx says PAPs may cover the full cost of a medicine or give a discount, are aimed at people who are uninsured or whose insurance does not cover the drug, and often ask for proof of income and residency. It adds that there is no standard enrolment process and each program sets its own criteria. That description comes from US consumer guidance and is not an Egyptian rule. We found no verified Egyptian program that calls itself a patient assistance program, so if you meet the term in Egypt, ask the sponsor what it means in that case.

What a patient support program usually includes

The Sacristan review found that the programs it examined mainly offered education alongside patient monitoring, most often by phone, with home delivery of medicines or devices in a minority of them, and that nurses were the professionals most often involved. The Newfoundland and Labrador page lists similar items for biosimilar products: injection training, nurse or case manager support, laboratory and vaccine services, and drug delivery or pharmacy coordination, with details varying by product. These services support how a medicine is used. A support program does not decide your treatment; your doctor does. Our guide on how to join a patient support program in Egypt walks through enrolment.

What a documented Egyptian program shows

Roche's Perjeta program report on the Access Accelerated platform (April 2020) is the clearest Egyptian example we found. It says the medicine is not reimbursed in the public system, and that the program's pricing scheme offers a free vial on each two vials purchased. The only eligibility condition it lists is that the patient buys the drug herself. Alongside that financial element, a third-party call centre registered patients and reminded them of dose due dates, providers handed out educational brochures, and the sponsor paid for HER2 testing for every breast cancer patient in Egypt, enrolled or not, and for imaging every three cycles. The report gives its start as 1 January 2016 in one place and June 2016 in another. Its 2017 to 2019 figures are submitted by the company. It defines adherence as the share of patients taking treatment as prescribed and reports 32%, 45% and 48% for 2017, 2018 and 2019, but the denominator it states refers to patients with noncommunicable diseases, which may be a template error. The lesson is the one this guide is about: in a single Egyptian program, assistance-style help with price and support-style reminders and education sat side by side.

What the evidence says about support programs

The Sacristan review reports that, across the 20 studies it kept, 75% achieved their stated objectives and the authors conclude that PSPs play a key role in treatment effectiveness, clinical outcomes and satisfaction. They also state that the studies varied widely, that only 45% compared a group with standard care, and that no conclusion can be drawn from those comparisons. The funding link to Eli Lilly is disclosed. Pharmaceutical Commerce adds criticisms: clinicians working for manufacturers may not give fully unbiased advice, enrolment can be complex, copayment assistance may make patients less sensitive to drug prices, and manufacturers typically do not disclose utilisation, costs or outcomes. It also says education alone, particularly written material without reinforcement, shows limited impact. These are reasons to ask questions, not reasons to avoid a program.

Why does any of this matter? WHO reported in 2003 that adherence among patients with chronic diseases averages only 50% in developed countries and is lower in developing countries, and that poor adherence is the primary reason medicines do not deliver their full benefit. Cost is only one barrier. A program that solves price but not understanding, or the reverse, will leave a gap.

Why the difference matters to you

  • Expectations. If you join a support program expecting it to pay for the medicine, you may be disappointed. If you ignore a program because you assume it is only a leaflet, you may miss useful nurse education.
  • Your data. Support programs collect health information to follow you up. Ask what is collected, who sees it and whether you can say yes to the service and no to other uses. Our guide to consent and privacy in patient support programs lists what to look for.
  • Your insurer. A program is not insurance. Ask your insurer separately about the medicine, and ask the program whether its help applies with insurance, instead of it or only if you pay privately. Our guide on whether a PSP covers medication cost goes deeper.
  • Your doctor. Neither kind of program changes your prescription. Tell your doctor which program you have joined.

An illustrative scenario in Mansoura

This example is illustrative, not a real case. A family in Mansoura brings home two leaflets from two different medicines prescribed for two relatives. Both say support. The daughter puts the table above beside each leaflet and phones both programs with the same three questions: what will we receive, what will we pay, and what happens to our data. The first program offers nurse education and reminder calls and no change in price. The second offers a pricing scheme only for patients who buy the medicine privately, plus a reminder line. They write the answers down, check with the insurer about the first medicine, and agree who in the family keeps the contact numbers. The point: the same word covered two different offers, and three questions separated them.

Eight questions to ask before you enrol

  1. Who sponsors this program, and who will contact me?
  2. Is it support, assistance or both: what will I actually receive?
  3. Will I pay anything for the service, and is the medicine's price a separate matter?
  4. What must I show to qualify: a prescription, a diagnosis, income, insurance status?
  5. Does it work with my insurance, instead of it, or only if I pay privately?
  6. What personal and health data do you collect, who sees it and for how long?
  7. Can I leave at any time, and does leaving affect my treatment?
  8. How do I report a side effect, and who tells my doctor?

If you design programs: use plain labels

Sponsors and delivery partners can reduce confusion by naming each element plainly in patient materials: education, nurse follow-up, reminders, testing support, and any price scheme, each with its written conditions. Patients should not have to decode a brand name to find out whether a program touches the price. Our guide to choosing a patient support program partner covers how sponsors can assess delivery partners.

How Hospitalia can help

Hospitalia is an Egypt-based integrated home healthcare and corporate medical services platform. In patient support it provides onboarding, education, follow-up and care coordination, with the scope of each program defined with the sponsoring organisation and the treating doctors. Hospitalia does not set medicine prices or provide financial assistance; any funding terms are set by the program sponsor. We can explain how programs work and what to ask.

Questions about patient support in Egypt?

Call 01063151838 or contact the patient support team and we will explain what to ask before you enrol.

Ask about patient support

Frequently asked questions

What is the difference between a patient support program and a patient assistance program?

A patient support program is a broad service around a treatment, such as education, nurse follow-up, reminders and coordination. A patient assistance program is narrower and helps with the cost of a medicine. The terms overlap, and a 2022 systematic review treats financial assistance as one category of patient support program, so judge a program by what it promises in writing.

What does a patient support program do?

A 2022 European review found that the programs it examined mainly offered education alongside patient monitoring, most often by phone, with home delivery in a minority of them and nurses the professionals most often involved. A support program helps you use a medicine as prescribed; it does not change your treatment, which stays with your doctor.

What is a patient assistance program, and how does it work?

In US consumer guidance, it is a program run by pharmaceutical companies, nonprofits or government agencies to help people without adequate insurance afford medicines, with a free supply or a discount, usually with income and residency rules. We found no Egyptian official definition, so ask the sponsor what a program covers in Egypt.

Does a patient assistance program exist in Egypt?

We found no verified Egyptian program that calls itself a patient assistance program. We did find a documented Egyptian program, Roche's Perjeta program, whose pricing scheme gave a free vial on each two vials purchased to patients who buy the medicine themselves, alongside reminders and testing support.

Do patient support programs improve adherence?

A 2022 review of 20 European studies reported that 75% achieved their objectives, but the studies varied widely, only 45% had a comparison group, the authors say no conclusion can be drawn from those comparisons, and the work was funded by Eli Lilly. Treat the evidence as encouraging but not conclusive.

Is it safe to share my health data with a support program?

Ask what is collected, who sees it, for what purpose and for how long, and whether consent to the service is separate from other uses. You should be able to leave at any time. Our guide to consent and privacy in patient support programs lists what to look for.

Related tags
#Patient Support Program vs Patient Assistance Program#Patient Support Program Egypt#Patient Assistance Program#What Is a Patient Support Program#PSP Egypt#Medication Access Egypt#Patient Enrolment

Related articles